Page last updated: 2024-10-24

negative regulation of establishment of endothelial barrier

Definition

Target type: biologicalprocess

Any process that stops, prevents or reduces the frequency, rate or extent of establishment of endothelial barrier. [GO_REF:0000058, GOC:als, GOC:TermGenie, PMID:24851274]

Negative regulation of establishment of endothelial barrier is a complex process that involves the coordinated action of various cellular signaling pathways and protein interactions. The endothelial barrier, formed by tight junctions and adherens junctions between endothelial cells, plays a crucial role in maintaining vascular integrity and regulating the passage of fluids, nutrients, and immune cells between the blood and surrounding tissues.

**Key Mechanisms Involved:**

1. **Regulation of Cell-Cell Adhesion:** The establishment of the endothelial barrier is largely dependent on the formation and maintenance of cell-cell junctions. These junctions involve specialized transmembrane proteins, such as cadherins and claudins, which mediate adhesion and tight seal formation between adjacent endothelial cells. Negative regulation of this process can occur through:
- **Downregulation of junctional protein expression:** Decreasing the levels of cadherins, claudins, or other junctional proteins can weaken the integrity of the barrier.
- **Disruption of junctional protein interactions:** Factors that interfere with the proper assembly or stability of junctional complexes can also compromise barrier function.
- **Activation of signaling pathways that promote junctional disassembly:** Certain signaling pathways, such as the RhoA pathway, can trigger the breakdown of cell-cell junctions, leading to barrier disruption.

2. **Control of Cell Shape and Polarity:** Endothelial cells exhibit a highly polarized structure, with distinct apical and basolateral domains. Maintaining this polarity is essential for barrier function. Disrupting cell polarity can lead to:
- **Loss of apical-basolateral differentiation:** This can impair the proper localization of junctional proteins and other barrier-related molecules.
- **Increased permeability:** Loss of polarity can lead to a more permeable barrier, allowing for the passage of larger molecules and cells.

3. **Regulation of Cytoskeletal Dynamics:** The cytoskeleton, a network of protein filaments within cells, plays a critical role in maintaining cell shape, adhesion, and barrier integrity. Negative regulation of cytoskeletal dynamics can occur through:
- **Depolymerization of actin filaments:** Actin filaments are crucial for the formation and stabilization of cell-cell junctions. Their depolymerization weakens the barrier.
- **Disruption of microtubule organization:** Microtubules are involved in the transport of proteins and vesicles necessary for barrier function. Disrupting microtubule organization can impair these processes.

4. **Modulation of Signaling Pathways:** Various signaling pathways contribute to the regulation of the endothelial barrier. Negative regulation can occur through:
- **Activation of pro-inflammatory pathways:** Inflammatory mediators, such as TNF-alpha and IL-1beta, can trigger signaling pathways that promote barrier disruption.
- **Inhibition of barrier-protective pathways:** Some signaling pathways, such as the PI3K/Akt pathway, promote barrier formation and stability. Inhibiting these pathways can weaken the barrier.

5. **Influence of Extracellular Matrix:** The extracellular matrix (ECM) surrounding endothelial cells provides structural support and influences cell behavior. Factors that disrupt ECM organization or composition can negatively affect barrier function.

**Consequences of Negative Regulation:**

Negative regulation of the establishment of the endothelial barrier can lead to a variety of pathological consequences, including:
- **Increased vascular permeability:** This can lead to edema (fluid accumulation) and tissue swelling.
- **Inflammation:** Barrier disruption can allow for the passage of immune cells and inflammatory mediators, contributing to tissue inflammation.
- **Tissue damage:** Increased permeability and inflammation can damage tissues, leading to organ dysfunction.
- **Disease progression:** Negative regulation of the endothelial barrier is implicated in the pathogenesis of various diseases, including sepsis, cancer, and diabetes.

**Conclusion:**

Negative regulation of the establishment of the endothelial barrier is a complex process involving multiple cellular mechanisms. Understanding these mechanisms is crucial for developing therapeutic strategies to prevent or reverse barrier dysfunction in various pathological conditions.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Sphingosine 1-phosphate receptor 3A sphingosine 1-phosphate receptor 3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q99500]Homo sapiens (human)
Vascular endothelial growth factor AA vascular endothelial growth factor A, long form that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15692]Homo sapiens (human)

Compounds (19)

CompoundDefinitionClassesRoles
4-phenylphenol4-phenylphenol: RN given refers to cpd without isomeric designation

biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4.
hydroxybiphenyls
4-phenylbenzoic acid4-phenylbenzoic acid: RN given refers to 4-carboxylic cpd
fingolimodfingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate.aminodiol;
primary amino compound
antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
bml 241BML 241: inhibits increase of intracellular calcium ion concentration; conflicting evidence of whether it acts on sphingosine-1-phosphate receptorsL-alpha-amino acid
sew2871SEW2871: structure in first sourceoxadiazole;
ring assembly
amentoflavonebiflavonoid;
hydroxyflavone;
ring assembly
angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite
sphingosine 1-phosphatesphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1

sphingosine 1-phosphate: RN given refers to (R-(R*,S*-(E)))-isomer; RN for cpd without isomeric designation not available 8/89
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
N-cyclohexyl-5-propyl-3-isoxazolecarboxamidearomatic amide;
heteroarene
N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamidearomatic amide;
heteroarene
proanthocyanidin a1procyanidin A1: from aqueous extract of peanut skin; structure in first sourceflavonoid oligomer
fty 720pfingolimod phosphate : A primary amino compound that is fingolimod in which one on the hydroxy groups has been converted into its dihydrogen phosphate derivative. It is the active metabolite of fingolimod.monoalkyl phosphate;
primary alcohol;
primary amino compound
antineoplastic agent;
immunosuppressive agent;
sphingosine-1-phosphate receptor agonist
jte 013JTE 013: an Edg-5 antagonist

JTE-013 : A semicarbazide derivative that is semicarbazide in which the amino group at position 2 is replaced by a [1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]amino group and the amino group adjacent to the carbonyl is replaced by a (2,6-dichloropyridin-4-yl)amino group. It is a potent S1P2 antagonist (IC50 = 17.6 nM).
chloropyridine;
pyrazolopyridine
anti-asthmatic agent;
anti-inflammatory agent;
antineoplastic agent;
osteogenesis regulator;
pro-angiogenic agent;
sphingosine-1-phosphate receptor 2 antagonist
ponesimodponesimod: structure in first source
fty 720p
VPC 23019VPC 23019 : A secondary carboxamide resulting from the formal condensation of the carboxy group of O-phospho-D-serine with the amino group of m-octylaniline. An analogue of sphingosine-1-phosphate (S1P), it is a potent antagonist for both S1P1 and S1P3 receptors. It can inhibit S1P-induced migration of thyroid cancer cells, ovarian cancer cells, and neural stem cells.

VPC23019: inhibits S1P3 receptor; structure in first source
aromatic amide;
D-serine derivative;
organic phosphate;
phosphoric ester;
secondary carboxamide
sphingosine-1-phosphate receptor 1 antagonist;
sphingosine-1-phosphate receptor 3 antagonist
cs-2100
cym-5442oxadiazole;
ring assembly
siponimodsiponimod: S1P receptor modulator
phosphomannopentaose sulfatephosphomannopentaose sulfate: structure in first source